Srilatha Edupuganti
A5016037005- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS drug development and treatment
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Mosquito-borne diseases and control
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 detection and testing
- vaccines and immunoinformatics approaches
- Respiratory viral infections research
- HIV/AIDS Research and Interventions
- Immunotherapy and Immune Responses
- Viral Infections and Vectors
- Immune Cell Function and Interaction
- Hepatitis C virus research
- Immune Response and Inflammation
- Blood groups and transfusion
- COVID-19 epidemiological studies
- Biosimilars and Bioanalytical Methods
- Virology and Viral Diseases
- Long-Term Effects of COVID-19
- Vaccine Coverage and Hesitancy
- Poxvirus research and outbreaks
- Insect symbiosis and bacterial influences
- Transgenic Plants and Applications
Emory University
2016-2025
HOPE Clinic
2015-2024
Grady Health System
2024
Grady Memorial Hospital
2024
Emory and Henry College
2009-2022
New York Proton Center
2022
Communities In Schools of Orange County
2022
Manhattan Institute for Policy Research
2022
Oregon Medical Research Center
2022
Lindsay Unified School District
2022
Coronavirus disease 2019 (COVID-19) represents a global crisis, yet major knowledge gaps remain about human immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We analyzed immune responses in 76 COVID-19 patients and 69 healthy individuals from Hong Kong Atlanta, Georgia, United States. In the peripheral blood mononuclear cells (PBMCs) of patients, we observed reduced expression leukocyte antigen class DR (HLA-DR) proinflammatory cytokines by myeloid as well impaired...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first emerged in late 2019 is responsible for a pandemic of illness. People infected with this highly contagious virus can present clinically inapparent, mild, or disease. Currently, the infection individuals and at population level being monitored by PCR testing symptomatic patients presence viral RNA. There an urgent need SARS-CoV-2 serologic tests to identify all individuals, irrespective clinical symptoms, conduct...
The 2009 pandemic H1N1 influenza demonstrated the global health threat of reassortant strains. Herein, we report a detailed analysis plasmablast and monoclonal antibody responses induced by infection in humans. Unlike antibodies elicited annual vaccinations, most neutralizing were broadly cross-reactive against epitopes hemagglutinin (HA) stalk head domain multiple from cells that had undergone extensive affinity maturation. Based on these observations, postulate plasmablasts producing...
Significance In this study, we address the issue of cross-reactivity between dengue virus (DENV) and Zika (ZIKV) by testing sera plasmablast-derived monoclonal antibodies from patients against ZIKV. We show that both acute convalescent potently bind neutralize ZIKV is also evident at level. demonstrate in vitro antibody-dependent enhancement infection presence dengue-induced antibodies. Our findings strongly suggest preexisting may modulate immune responses to infection. These data are...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, angiotensin-converting enzyme (ACE2)–competing antibodies elicited by messenger RNA (mRNA) vaccine mRNA-1273 7 months. Cross-reactive...
Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in United States are highly effective, breakthrough infections occurring. Data needed on serial of homologous boosters (same as primary vaccine) and heterologous (different from fully vaccinated recipients.In this phase 1-2, open-label clinical trial conducted at 10 sites States, adults who had completed a Covid-19 vaccine regimen least 12 weeks earlier no reported history...
SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide pandemic, and there pressing need to understand development, specificity, neutralizing potency of humoral immune responses during acute infection. We report cross-sectional study antibody receptor-binding domain (RBD) spike protein neutralization activity in cohort 44 hospitalized COVID-19 patients. RBD-specific IgG are detectable all patients 6 days after PCR confirmation. Isotype switching occurs rapidly,...
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 patients longitudinally up 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting generation longer-lived plasma cells. infection also boosts antibody titers SARS-CoV-1 common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well...
We have previously shown that broadly neutralizing antibodies reactive to the conserved stem region of influenza virus hemagglutinin (HA) were generated in people infected with 2009 pandemic H1N1 strain. Such are rarely seen humans following infection or vaccination seasonal strains. However, important question remained whether inactivated vaccine, like infection, could also induce these antibodies. To address this question, we analyzed B-cell responses 24 healthy adults immunized vaccine...
Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear.
The different sialic acid (serogroups B, C, Y, and W-135) nonsialic (serogroup A) capsular polysaccharides expressed by Neisseria meningitidis are major virulence factors used as epidemiologic markers vaccine targets. However, the identification of meningococcal isolates with similar genetic but expressing suggests that clones can switch type capsule they express. We identified, except for capsule, isogenic serogroups B [(α2→8)-linked polysialic acid] C [(α2→9)-linked from an outbreak...
The live yellow fever vaccine (YF-17D) offers a unique opportunity to study memory CD8(+) T cell differentiation in humans following an acute viral infection. We have performed comprehensive analysis of the virus-specific response using overlapping peptides spanning entire genome. Our results showed that YF-17D induces broad targeting several epitopes within each protein. identified dominant HLA-A2-restricted epitope NS4B protein and used tetramers specific for this track over 2 year period....
The Zika virus epidemic and associated congenital infections have prompted rapid vaccine development. We assessed two new DNA vaccines expressing premembrane envelope structural proteins.We did phase 1, randomised, open-label trials involving healthy adult volunteers. VRC 319 trial, done in three centres, plasmid VRC5288 (Zika Japanese encephalitis chimera), the 320, one centre, VRC5283 (wild-type virus). Eligible participants were aged 18-35 years VRC19 18-50 320. Participants randomly...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pandemic that has infected over 36 million and killed 1 people. Informed implementation government public health policies depends on accurate data SARS-CoV-2 immunity at a population scale. We hypothesized detection salivary antibodies could serve as noninvasive alternative to serological testing for monitoring infection seropositivity
Significance Vaccination is the most effective means of attaining protection against influenza viruses. However, constantly evolving nature viruses enables them to escape preexisting immune surveillance, and thus thwarts public health efforts control annual epidemics occasional pandemics. One solution elicit antibodies directed highly conserved epitopes, such as those within stem region HA, principal target virus-neutralizing antibody responses. This study shows that vaccines induce...
<h3>Importance</h3> Preventive interventions are needed to protect residents and staff of skilled nursing assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may confer rapid protection SARS-CoV-2 infection COVID-19. <h3>Objective</h3> To determine the effect bamlanivimab on incidence among <h3>Design, Setting, Participants</h3> Randomized, double-blind, single-dose, phase 3 trial that enrolled 74...
OBJECTIVES: We aimed to measure severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological responses in children hospitalized with multisystem inflammatory (MIS-C) compared those disease 2019 (COVID-19), Kawasaki (KD), and pediatric controls. METHODS: From March 17, 2020, May 26, we prospectively identified MIS-C (n = 10), symptomatic COVID-19 KD 5) controls 4) at Children’s Healthcare of Atlanta. With institutional review board approval, obtained prospective residual blood...
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost generate protective immunity. We assess the magnitude and short-term durability antibodies after homologous heterologous boosting with mRNA Ad26.COV2.S vaccines. All prime-boost combinations substantially increase neutralization titers Omicron, although boosted decline rapidly within months from peak response...
Identifying HIV-1 envelope (Env) traits associated with neutralization cross-reactivity is crucial for vaccine design. Variable loops 1 and 2 (V1V2), positioned at the Env trimer apex, are key regions linked to neutralization. We describe non-canonical cysteine (Cys) residues in V1 that enriched individuals elite breadth. Analyzing over 65,000 sequences from CATNAP database, AMP trials, longitudinal cohorts (SHCS, ZPHI, CAPRISA), we found variants extra Cys present low levels fluctuate time....
Background. DNA vaccines have been very poorly immunogenic in humans but an effective priming modality prime-boost regimens. Methods to increase the immunogenicity of are needed.
Human infections with avian influenza A/H7N9 have resulted in high morbidity and mortality China.To compare safety immunogenicity of different doses A/Shanghai/2/13 (H7N9) vaccine mixed or without the MF59 adjuvant.Multicenter, randomized, double-blind, phase 2 trial at 4 US sites enrolled 700 adults aged 19 to 64 years beginning September 2013; 6-month follow-up was completed May 2014.The H7N9 inactivated virus administered intramuscularly on days 0 21 nominal 3.75, 7.5, 15, 45 µg...